{"product_id":"tesamorelin-5mg","title":"Tesamorelin 5mg","description":"\u003cp\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/1007\/3581\/1927\/files\/Tesa_5mg_gloss.png?v=1779035727\" alt=\"\"\u003e\u003c\/p\u003e\n\u003cp\u003eTesamorelin 5mg is a synthetic analogue of growth hormone-releasing hormone (GHRH) designed for research and laboratory use. Tesamorelin is a stabilised 44-amino acid GHRH peptide with a trans-3-hexenoic acid modification at the N-terminus, conferring enhanced stability relative to endogenous GHRH(1–44). It has been investigated in preclinical and clinical research settings for its effects on GH and IGF-1 axis stimulation, visceral adiposity, and metabolic regulation. Each vial is manufactured to pharmaceutical-grade purity standards to ensure consistency and reliability in research settings. Ideal for qualified researchers and institutions studying GHRH receptor pharmacology, GH axis modulation, and metabolic biology. Store in a cool, dry place away from direct light. For research purposes only. Not intended for human or veterinary use.\u003c\/p\u003e\n\u003cp\u003eSpecifications: Active Ingredient: Tesamorelin (synthetic GHRH analogue) Concentration: 5mg per vial Molecular Formula: C₂₂₁H₃₆₆N₆₀O₆₇S Molecular Weight: 5,202.8 g\/mol Structure: 44-amino acid GHRH analogue with N-terminal trans-3-hexenoic acid modification CAS Number: 86168-78-7 Purity: ≥98% (HPLC) Form: Lyophilised powder Appearance: White to off-white lyophilised powder pH (reconstituted): 4.0–5.5 Endotoxin Level: \u0026lt;5 EU\/vial Storage: 2–8°C (refrigerated) Shelf Life: 24 months from manufacture date Reconstitution: Sterile water for injection Intended Use: Laboratory and research applications only\u003c\/p\u003e\n\u003cp\u003eStorage Before Reconstitution: Store in original sealed vial at 2–8°C, protected from direct light and moisture. Stable for 24 months from manufacture date. Do not freeze. Minimise temperature fluctuations. Storage After Reconstitution: Store reconstituted solution at 2–8°C, protected from light. Use aseptic technique throughout. Avoid repeated freeze-thaw cycles; if freezing is necessary, use single-use aliquots at −20°C for up to 3 months. For research use only. Not intended for human or veterinary use.\u003c\/p\u003e\n\u003ch2\u003eResearch References\u003c\/h2\u003e\n\u003cp\u003eThe following peer-reviewed studies and publications are provided for informational and scientific reference purposes only. They do not constitute medical claims or endorsements of this product for any therapeutic use.\u003c\/p\u003e\n\u003col\u003e\n\u003cli\u003e\n\u003cstrong\u003eTesamorelin: Design and GHRH Receptor Pharmacology\u003c\/strong\u003e\u003cbr\u003eFalutz J, et al. (2007). \u003cem\u003eMetabolic effects of a growth hormone–releasing factor in patients with HIV.\u003c\/em\u003e New England Journal of Medicine, 357(23), 2359–2370. \u003ca href=\"https:\/\/doi.org\/10.1056\/NEJMoa072375\"\u003ehttps:\/\/doi.org\/10.1056\/NEJMoa072375\u003c\/a\u003e\u003cbr\u003ePivotal Phase 3 clinical research study demonstrating tesamorelin’s ability to significantly reduce visceral adipose tissue and elevate IGF-1 levels via sustained GHRH receptor activation, establishing its pharmacodynamic profile and providing the key translational reference for tesamorelin GH-axis research.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTesamorelin and GH\/IGF-1 Axis Stimulation\u003c\/strong\u003e\u003cbr\u003eFalutz J, et al. (2010). \u003cem\u003eEffects of tesamorelin (TH9507), a growth hormone-releasing factor analogue, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.\u003c\/em\u003e Journal of Acquired Immune Deficiency Syndromes, 53(3), 311–322. \u003ca href=\"https:\/\/doi.org\/10.1097\/QAI.0b013e3181cbdaff\"\u003ehttps:\/\/doi.org\/10.1097\/QAI.0b013e3181cbdaff\u003c\/a\u003e\u003cbr\u003eRandomised, placebo-controlled trial with safety extension evaluating tesamorelin’s sustained effects on GH and IGF-1 secretion and visceral fat reduction, providing long-term pharmacodynamic and tolerability data relevant to GHRH analogue research protocols.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eGHRH Receptor Structure and Agonist Binding\u003c\/strong\u003e\u003cbr\u003eMayo KE, et al. (1992). \u003cem\u003eMolecular cloning and expression of a pituitary-specific receptor for growth hormone-releasing hormone.\u003c\/em\u003e Molecular Endocrinology, 6(10), 1734–1744. \u003ca href=\"https:\/\/doi.org\/10.1210\/mend.6.10.1333056\"\u003ehttps:\/\/doi.org\/10.1210\/mend.6.10.1333056\u003c\/a\u003e\u003cbr\u003eReports the cloning and characterisation of the GHRH receptor (GHRHR), establishing the molecular target through which tesamorelin exerts its GH-releasing effects and providing the structural and signalling context for GHRH receptor agonist research.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTesamorelin and Visceral Adiposity: Metabolic Research Context\u003c\/strong\u003e\u003cbr\u003eStanley TL, et al. (2012). \u003cem\u003eEffect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.\u003c\/em\u003e JAMA, 312(4), 380–389. \u003ca href=\"https:\/\/doi.org\/10.1001\/jama.2014.8334\"\u003ehttps:\/\/doi.org\/10.1001\/jama.2014.8334\u003c\/a\u003e\u003cbr\u003eRandomised clinical trial demonstrating tesamorelin’s significant reduction of visceral and hepatic fat via GH\/IGF-1 axis activation, providing quantitative metabolic and body composition data relevant to researchers studying GHRH analogue effects on lipid metabolism and adipose tissue biology.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTesamorelin and Cognitive Function Research\u003c\/strong\u003e\u003cbr\u003eBaker LD, et al. (2012). \u003cem\u003eEffects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults.\u003c\/em\u003e Archives of Neurology, 69(11), 1420–1429. \u003ca href=\"https:\/\/doi.org\/10.1001\/archneurol.2012.1970\"\u003ehttps:\/\/doi.org\/10.1001\/archneurol.2012.1970\u003c\/a\u003e\u003cbr\u003eRandomised controlled trial investigating tesamorelin’s effects on cognitive function in older adults and those with mild cognitive impairment, demonstrating improvements in executive function and verbal memory — expanding the research scope of GHRH analogue studies into neuroendocrine and cognitive biology.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003e\u003cem\u003eAll references are cited for scientific context only. This product is supplied strictly for in vitro laboratory research. It is not approved for human or veterinary use.\u003c\/em\u003e\u003c\/p\u003e","brand":"Mutant Peptides","offers":[{"title":"Default Title","offer_id":53248637894999,"sku":"TSM5","price":23.99,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1007\/3581\/1927\/files\/Tesa_5mg_gloss.png?v=1779035728","url":"https:\/\/www.mutantpeptides.com\/products\/tesamorelin-5mg","provider":"Mutant Peptides Ltd","version":"1.0","type":"link"}